- Home
- INBS vs NEUP Comparison
INBS vs NEUP Comparison
Compare INBS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBS
- NEUP
- Stock Information
- Founded
- INBS 2016
- NEUP 1996
- Country
- INBS United States
- NEUP United States
- Employees
- INBS N/A
- NEUP N/A
- Industry
- INBS Medical Specialities
- NEUP
- Sector
- INBS Health Care
- NEUP
- Exchange
- INBS Nasdaq
- NEUP Nasdaq
- Market Cap
- INBS 11.7M
- NEUP 12.7M
- IPO Year
- INBS N/A
- NEUP N/A
- Fundamental
- Price
- INBS $1.72
- NEUP $8.48
- Analyst Decision
- INBS
- NEUP Strong Buy
- Analyst Count
- INBS 0
- NEUP 1
- Target Price
- INBS N/A
- NEUP $21.00
- AVG Volume (30 Days)
- INBS 253.7K
- NEUP 41.0K
- Earning Date
- INBS 09-18-2025
- NEUP 08-15-2025
- Dividend Yield
- INBS N/A
- NEUP N/A
- EPS Growth
- INBS N/A
- NEUP N/A
- EPS
- INBS N/A
- NEUP 0.00
- Revenue
- INBS $2,936,472.00
- NEUP $15,662,715.00
- Revenue This Year
- INBS $280.88
- NEUP N/A
- Revenue Next Year
- INBS $126.26
- NEUP N/A
- P/E Ratio
- INBS N/A
- NEUP $5,002.94
- Revenue Growth
- INBS 3.87
- NEUP N/A
- 52 Week Low
- INBS $1.00
- NEUP $2.90
- 52 Week High
- INBS $3.00
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- INBS 48.37
- NEUP N/A
- Support Level
- INBS $1.76
- NEUP N/A
- Resistance Level
- INBS $2.27
- NEUP N/A
- Average True Range (ATR)
- INBS 0.18
- NEUP 0.00
- MACD
- INBS -0.01
- NEUP 0.00
- Stochastic Oscillator
- INBS 25.56
- NEUP 0.00
About INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.